Brown & Brown reported second quarter 2026 results that missed revenue expectations but showed strong year-on-year growth. Revenue rose 30.4% to $1.68 billion, below the $1.72 billion analyst estimate. Management attributed performance to strong contingent commissions, effective acquisition integration, and improved sales processes. CEO J. Powell Brown said the company's enhanced sales model is building momentum with aligned teams generating new business wins. Operating margin declined year-over-year to 22.9% from 24.2%, though the company made progress controlling expenses. Adjusted EBITDA of $611 million beat analyst estimates of $603.1 million. During the earnings call, analysts questioned MGA competition impacts, European expansion plans, and technology investment costs. Management stressed disciplined underwriting and confirmed synergy targets remain unchanged.

Brown & Brown reported Q2 2026 results with revenue of $1.676 billion and net income of $288 million. The insurance broker's shares closed at $70.40, posting a 22.16% gain over 90 days but down 9.30% year-to-date and 23.00% over one year. Valuation models suggest a fair value of $75.63, indicating the stock is 6.9% undervalued. The company's diversified portfolio across geographies and business lines supports earnings stability. However, the price-to-earnings ratio of 19.8x exceeds both the US insurance industry average of 12.1x and the stock's fair ratio of 12.5x. Risks include rising pharmacy costs in benefits and potential Florida legislative changes that could pressure margins.

Brown & Brown shares jumped 5% after reporting second-quarter results. The insurance brokerage firm's revenue grew 30.4% year-over-year to $1.68 billion, slightly below analyst estimates of $1.72 billion. Adjusted earnings per share came in at $1.07, exactly meeting Wall Street expectations. The positive market reaction suggests investors focused on strong top-line growth and profit targets rather than the minor revenue miss. The shares are down 5.9% year-to-date and trading at $73.05, which is 28.8% below their 52-week high of $102.58 from July 2025. Last month, Morgan Stanley downgraded the stock to "Underweight", citing concerns about organic growth reset and a softer pricing cycle.